
|Videos|November 7, 2014
Using the LGR5 Protein as a Biomarker in Thyroid Cancer
Author(s)Brittany N. Bohinc, MD
Brittany N. Bohinc, MD, Division of Endocrinology, Duke University, discusses the potential to use LGR5 as a biomarker in papillary thyroid cancer.
Advertisement
Clinical Pearls
Brittany N. Bohinc, MD, Division of Endocrinology, Duke University, discusses the potential to use LGR5 as a biomarker in papillary thyroid cancer.
- LGR5 is a protein that marks cancer stems cells. It is known to be important in colorectal cancer and gastric cancer.
- Using two methods, researchers found that LGR5 was highly expressed in papillary thyroid cancer.
- LGR5 in thyroid cancer is associated with lymph node number, lymph node metastases, tumor size, T stage, N stage, extrathyroidal extension, lymphovascular invasion, and macroscopic extension.
- LGR5 could be used as a biomarker for novel therapeutics or risk stratification for surgery.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































